Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
0 hedge funds and large institutions have $0 invested in Bellicum Pharmaceuticals, Inc. in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $173K → $0 (-$173K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$167K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$4.22K |
| 3 |
PGAM
Princeton Global Asset Management
Princeton,
New Jersey
|
-$37 |
BLCM Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2023, worth a combined $0 — down 100% from $173K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BLCM and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Boxer Capital, exiting entirely with an estimated $167K sold.
- 0 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2023, down from 4 in Q2 2023.
- Funds reported $0 of Bellicum Pharmaceuticals, Inc. stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2023 and 3 closed out, a net change of -3 holders.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2023 was Boxer Capital, an estimated $167K sold.
Based on aggregated 13F filings for Q3 2023.